| Di | Heat Biologics Aktionäre sind in Rage – Diese Informationen werden Ihnen vorenthalten | Felix Haupt |
| 01.12.19 | Schocknews für Heat Biologics Aktionäre am Freitag – Deshalb stark im Minus (Kommende Woche geht’s tiefer) | Ratgeber-Aktien |
| 20.11.19 | Heat Biologics: Aktie explodiert - darauf ist jetzt zu achten! | sharedeals.de |
| 20.11.19 | Heat Biologics: Aktie explodiert – darauf ist jetzt zu achten! | Finanztrends |
| |
| 14.08.19 | Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update | ACCESSWIRE |
| 12.08.19 | Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110 | ACCESSWIRE |
| 08.08.19 | Heat auf Deutschland-Tour: Mehr als Kaffeeklatsch für Bagholders? | sharedeals.de |
| 07.08.19 | Heat Biologics CEO and Lead Director to Participate in German Investor Forums | ACCESSWIRE |
| 19.07.19 | No Brainer Club – Positive Erfahrungen nach +907% im 1. Jahr! | sharedeals.de |
| |
| 09.07.19 | Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial | ACCESSWIRE |
| 04.06.19 | Heat: Neue Mega-Daten lassen kaum noch Zweifel zu | sharedeals.de |
| 03.06.19 | Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure | ACCESSWIRE |
| 20.05.19 | Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference | ACCESSWIRE |
| 15.05.19 | Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update | ACCESSWIRE |
| 06.05.19 | Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai | ACCESSWIRE |
| 18.04.19 | Heat Biologics CEO to Present at the ThinkEquity Conference in New York City | ACCESSWIRE |
| 02.04.19 | Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019 | ACCESSWIRE |
| 28.03.19 | Heat Biologics: Pharmaindustrie signalisiert „großes Interesse“ | sharedeals.de |
| 28.03.19 | Heat Biologics Reports 2018 Results and Provides Corporate Update | ACCESSWIRE |
| 21.03.19 | Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy | ACCESSWIRE |
| 06.03.19 | Heat Biologics: In China wird’s jetzt richtig heiß… | sharedeals.de |
| 05.03.19 | Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai | ACCESSWIRE |
| 01.03.19 | Heat Biologics: Shortseller spielen Katz und Maus nach Mega-Daten | sharedeals.de |
| 28.02.19 | Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium | ACCESSWIRE |
| 28.02.19 | Heat Biologics legt los – ASCO-Präsentation LIVE auf sharedeals.de | sharedeals.de |
| 27.02.19 | Evotec, Medigene, Paion, MorphoSys – wir haben es gesagt! | sharedeals.de |
| 26.02.19 | Heat Biologics: Diese Daten sind der Jackpot! | sharedeals.de |
| 25.02.19 | Heat Biologics LIVE: Diese Daten können die Welt verändern! | sharedeals.de |
| 28.01.19 | Heat Biologics: Rakete wieder startklar – Countdown geschaltet! | sharedeals.de |
| 14.01.19 | Heat: Mega-Daten in Sicht – und jetzt auch noch Keytruda! | sharedeals.de |
| 14.01.19 | UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial | ACCESSWIRE |
| 14.01.19 | Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial | ACCESSWIRE |
| 10.01.19 | Heat Biologics Provides Clinical and Business Update | ACCESSWIRE |
| 08.01.19 | Heat Biologics kündigt Daten-Präsentation auf ASCO an | sharedeals.de |
| 08.01.19 | Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium | ACCESSWIRE |
| 04.01.19 | Heat Biologics to Present at Biotech Showcase 2019 in California | ACCESSWIRE |
| 29.11.18 | Heat Biologics: WICHTIGE Aktionärsinitiative gestartet! | sharedeals.de |
| 26.11.18 | Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering | ACCESSWIRE |
| 26.11.18 | Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum | ACCESSWIRE |
| 21.11.18 | Heat Biologics, Inc. Prices $12,000,000 Public Offering | ACCESSWIRE |
| 21.11.18 | Heat Biologics: Kursgeschenke – das müssen Sie jetzt wissen! | sharedeals.de |
| 20.11.18 | Heat Biologics, Inc. Announces Proposed Public Offering | ACCESSWIRE |
| 15.11.18 | Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update | ACCESSWIRE |
| 22.10.18 | Heat Biologics to Present at Precision: Lung Cancer World R&D Summit | ACCESSWIRE |
| 19.10.18 | Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City | ACCESSWIRE |
| 10.10.18 | Heat Biologics to Present at the 2018 BIO Investor Forum | ACCESSWIRE |
| 03.09.18 | Heat Biologics: «Wenn wir weiter gute Daten veröffentlichen…» | sharedeals.de |
| 01.08.18 | Heat Biologics: Das nächste Kursfeuerwerk ist nicht mehr weit! | sharedeals.de |
| 10.07.18 | Heat Biologics: Top-Analyst startet Kaufstudie mit Kursziel 11 USD | sharedeals.de |
| 18.06.18 | Wirecard und Dialog Semiconducter: Darum lohnt der Verkauf! | sharedeals.de |
Zum Seitenanfang
